Thanks mostly to FDA approval of a supplementary New Drug Application (sNDA) for Acetadote (N-acetylcysteine for injection), Cumberland stock has been on a monumental run in December 2024.

Acetadote is supplied as a 20% solution (200mg/mL) in a 30mL single-dose vial that must be diluted prior to intravenous administration. Total injection volume will vary based on the patient’s ...

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Free Report) in a research note released on Sunday. The brokerage issued a hold rating on the specialty ...

FDA approved a simplified Acetadote dosing regimen, reducing errors and serious reactions while maintaining effectiveness. Acetadote addresses liver injury from acetaminophen toxicity, the leading ...

On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest ...

Shares of Cumberland Pharmaceuticals (CPIX) doubled on Tuesday morning, reaching levels not seen since March 2023, following FDA approval of a new dosing regimen for its liver drug, Acetadote.

The Food and Drug Administration (FDA) has approved a new dosing regimen for Acetadote ® (n-acetylcysteine [NAC] for injection), an antidote for acetaminophen overdose. According to Cumberland ...

The FDA has approved a supplemental New Drug Application (sNDA) for Cumberland Pharmaceuticals Inc.’s Acetadote (N-acetylcysteine for injection) product, an intravenous (IV) formulation of ...